



# MROQC Breast Project: Clinical Tip Sheet



## Breast Eligibility Criteria

### Inclusion Criteria:

- **Newly diagnosed**, female breast cancer patients, 18 years and older
- Diagnosed with invasive breast cancer or ductal carcinoma in situ (DCIS)
- To be treated with breast-conserving surgery and **either partial or whole breast radiotherapy**.
- Breast conservation patients treated with neoadjuvant chemotherapy, concurrent or sequential systemic therapy, and radiation to regional nodes are eligible.
- Patients with metastatic breast cancer are eligible if being treated to the whole breast.

### Exclusion Criteria:

- Patients referred for **post-mastectomy** radiotherapy
- Patients referred for treatment of chest wall **recurrences**
- Any other indication for radiotherapy in a patient who has undergone mastectomy.
- Patients being treated for synchronous **bilateral breast cancer**
- Patients who have been **previously treated with radiation to the thoracic region**.

*Additional inclusion and exclusion criteria are listed on page 2 of the breast and lung eligibility criteria document.*

Data Collection Time Points	Pre RT Eval	1 <sup>st</sup> Week of RT	Last Week of RT	3 Months After RT	Annual Post RT end date
Follow-up Windows				2 months-4 months	9 months-15 months
Breast Baseline & Chemo Forms (CDA)	B5 (Baseline)		B6 (Chemo Post RT)	B6 (Update If Needed)	
Patient Questionnaires	B1		B3	B4	B13
Breast RT Toxicity Eval (Provider)		B7	B9	B10	B14

## Data Collection Timepoints- Ultra hypo-fractionation/"5 fractionations"

Time Points	Pre RT Eval	1 <sup>st</sup> Week of RT	Last Week of RT	3 Months After RT	Annual Post RT end date
Follow-up Windows				2 months-4 months	9 months-15 months
Breast Baseline & Chemo Forms (CDA)	B5 (Baseline)		B6 (Chemo Post RT)	B6 (Update If Needed)	
Patient Questionnaires	B1		X	B4	B13
Breast RT Toxicity Eval (Provider)		B7	B9* (RT end date only)	B10	B14

### Project Upgrade Dates

Version #	Upgrade Date
V 1→2	January 2014
V 2→V 3	August 28,2017
V3→V 4	May 7,2019
V4→V 5	February 17,2021

\*B9: The CDA should only submit the RT end date

### Project Changes

- The weekly provider(B8) and weekly patient (B2) forms are no longer collected on breast patients who started treatment on or after **1/1/21**.
- **2/17/21**: Patients receiving partial breast radiotherapy are eligible.
- **6/28/2022**: New cannabis use questions added to **B1 & B3** forms and smoking cessation questions added to **B5**.
- **12/9/22**: Cannabis questions updated on patient forms and questions added to physician and patient forms to track lymphedema. A question about the type of patient encounter added to all physician forms.
- **8/1/23**: Year 2 and year 3 annual time points removed.
- **9/18/23**: 2-week follow-up is no longer required on patients ending treatment on 9/18/23 onward.

### Reminders

- Follow-up times points apply to all breast patients. Follow-up data can be collected during in-person or telehealth appointments.
- Patients with metastatic breast cancer are **eligible if bone is not a part of the target**.